(Q33396664)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21833591%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

title

Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21833591%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21833591%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Vanna Chiarion Sileni

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21833591%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Paola Queirolo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21833591%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Alessandro Testori

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21833591%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Luana Calabro'

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21833591%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Pier Francesco Ferrucci

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21833591%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Michele Maio

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21833591%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

author name string

Ruggero Ridolfi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21833591%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Ruth Plummer

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21833591%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Monica Boitano

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21833591%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Costanza De Rossi

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21833591%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Anna Maria Di Giacomo

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21833591%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Laura Ridolfi

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21833591%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Maresa Altomonte

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21833591%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Clelia Miracco

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21833591%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Angelo Balestrazzi

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21833591%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

publication date

11 August 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21833591%20AND%20SRC:MED&resulttype=core&format=json

Cancer Immunology, Immunotherapy

10 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21833591%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

volume

61

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21833591%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21833591%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

page(s)

41-48

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21833591%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00262-011-1089-0

10 February 2020

exact match

0 references

cites work

Incidence of uveal melanoma in the United States: 1973-1997.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1089-0

Management of posterior uveal melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1089-0

Survival in patients with uveal melanoma in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1089-0

Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1089-0

Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1089-0

Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1089-0

A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1089-0

Prognostic factors in small malignant melanomas of choroid and ciliary body

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1089-0

Lymphocytic infiltration in uveal malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1089-0

A prognostic model and staging for metastatic uveal melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1089-0

A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1089-0

Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1089-0

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1089-0

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1089-0

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1089-0

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1089-0

Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1089-0

Anti-CTLA4 Antibody Clinical Trials in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1089-0

Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1089-0

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1089-0

The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1089-0

Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1089-0

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1089-0

Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1089-0

Durable responses and long-term progression-free survival observed in a phase II study of MDX-010 alone or in combination with dacarbazine (DTIC) in metastatic melanoma

21 January 2018

1 reference

18 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1200/JCO.2005.23.16_SUPPL.7525

Identifiers

DOI

10.1007/S00262-011-1089-0

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21833591%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

10 February 2020

1046605974

0 references

1 reference